U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from Books

Items: 1 to 20 of 24

1.
The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population
Mohammad Hadi Abbasian, Nafiseh Ansarinejad, Bahareh Abbasi, Masoud Iravani, Tayeb Ramim, Fahime Hamedi, Ali M. Ardekani
Avicenna J Med Biotechnol. 2020 Jul-Sep; 12(3): 157–164.
PMCID:
PMC7368113
AbstractArticlePDF–647K
2.
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
Carin A. T. C. Lunenburg, Cathelijne H. van der Wouden, Marga Nijenhuis, Mandy H. Crommentuijn-van Rhenen, Nienke J. de Boer-Veger, Anne Marie Buunk, Elisa J. F. Houwink, Hans Mulder, Gerard A. Rongen, Ron H. N. van Schaik, Jan van der Weide, Bob Wilffert, Vera H. M. Deneer, Jesse J. Swen, Henk-Jan Guchelaar
Eur J Hum Genet. 2020 Apr; 28(4): 508–517. Published online 2019 Nov 19. doi: 10.1038/s41431-019-0540-0
PMCID:
PMC7080718
AbstractArticlePDF–653K
3.
DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
Forike K. Martens, Daan W. Huntjens, Tessel Rigter, Meike Bartels, Pierre M. Bet, Martina C. Cornel
Front Pharmacol. 2019; 10: 1609. Published online 2020 Jan 28. doi: 10.3389/fphar.2019.01609
PMCID:
PMC6997151
AbstractArticlePDF–408K
4.
Variation in Actionable Pharmacogenetic Markers in Natives and Mestizos From Mexico
Vanessa Gonzalez-Covarrubias, Marlet Morales-Franco, Omar F. Cruz-Correa, Angélica Martínez-Hernández, Humberto García-Ortíz, Francisco Barajas-Olmos, Alma Delia Genis-Mendoza, José Jaime Martínez-Magaña, Humberto Nicolini, Lorena Orozco, Xavier Soberón
Front Pharmacol. 2019; 10: 1169. Published online 2019 Oct 10. doi: 10.3389/fphar.2019.01169
PMCID:
PMC6796793
AbstractArticlePDF–1.0M
5.
TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5—Fluorouracil-Based Chemotherapy
Yvonne L. Chao, Carey K. Anders
Clin Breast Cancer. Author manuscript; available in PMC 2019 Sep 25.
Published in final edited form as: Clin Breast Cancer. 2018 Jun; 18(3): e301–e304. Published online 2017 Aug 19. doi: 10.1016/j.clbc.2017.08.006
PMCID:
PMC6759830
ArticlePDF–297K
6.
Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer
Pashtoon Murtaza Kasi, Tyler Koep, Erica Schnettler, Faisal Shahjehan, Vaishnavi Kamatham, Candice Baldeo, Caren L. Hughes
Technol Cancer Res Treat. 2019; 18: 1533033819873924. Published online 2019 Sep 18. doi: 10.1177/1533033819873924
PMCID:
PMC6753511
AbstractArticlePDF–198K
7.
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
Vincenzo De Falco, Maria Iole Natalicchio, Stefania Napolitano, Nicola Coppola, Giovanni Conzo, Erika Martinelli, Nicoletta Zanaletti, Pasquale Vitale, Emilio Francesco Giunta, Maria Teresa Vietri, Pietro Paolo Vitiello, Davide Ciardiello, Anna Marinaccio, Ferdinando De Vita, Fortunato Ciardiello, Teresa Troiani
Medicine (Baltimore) 2019 May; 98(21): e15759. Published online 2019 May 24. doi: 10.1097/MD.0000000000015759
PMCID:
PMC6571425
AbstractArticlePDF–185K
8.
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients
Chara Stavraka, Athanasios Pouptsis, Leroy Okonta, Karen DeSouza, Philip Charlton, Matthaios Kapiris, Anthony Marinaki, Eleni Karapanagiotou, Dionysis Papadatos-Pastos, Janine Mansi
Breast Cancer Res Treat. 2019; 175(2): 511–517. Published online 2019 Feb 12. doi: 10.1007/s10549-019-05144-9
PMCID:
PMC6533219
AbstractArticlePDF–554K
9.
The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study
Francesco Iachetta, Candida Bonelli, Alessandra Romagnani, Raffaella Zamponi, Lorenzo Tofani, Enrico Farnetti, Davide Nicoli, Angela Damato, Maria Banzi, Bruno Casali, Carmine Pinto
Br J Cancer. 2019 Apr 16; 120(8): 834–839. Published online 2019 Mar 12. doi: 10.1038/s41416-019-0423-8
PMCID:
PMC6474277
AbstractArticlePDF–391K
10.
Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma
Lisa M. Velez-Velez, Caren L. Hughes, Pashtoon Murtaza Kasi
Front Pharmacol. 2018; 9: 1309. Published online 2018 Nov 15. doi: 10.3389/fphar.2018.01309
PMCID:
PMC6249237
AbstractArticlePDF–240K
11.
Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications
Candice Baldeo, Prakash Vishnu, Kabir Mody, Pashtoon Murtaza Kasi
SAGE Open Med Case Rep. 2018; 6: 2050313X18786405. Published online 2018 Jul 4. doi: 10.1177/2050313X18786405
PMCID:
PMC6041857
AbstractArticlePDF–507K
12.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Ursula Amstutz, Linda M. Henricks, Steven M. Offer, Julia Barbarino, Jan H.M. Schellens, Jesse J. Swen, Teri E. Klein, Howard L. McLeod, Kelly E. Caudle, Robert B. Diasio, Matthias Schwab
Clin Pharmacol Ther. Author manuscript; available in PMC 2019 Feb 1.
Published in final edited form as: Clin Pharmacol Ther. 2018 Feb; 103(2): 210–216. Published online 2017 Nov 20. doi: 10.1002/cpt.911
PMCID:
PMC5760397
AbstractArticlePDF–81K
13.
First Case of Foot Drop Associated with Capecitabine in a Patient with Thymidylate Synthase Polymorphism
Andrew B Wilks, Muhammad W Saif
Cureus. 2017 Jan; 9(1): e995. Published online 2017 Jan 24. doi: 10.7759/cureus.995
PMCID:
PMC5325748
AbstractArticlePDF–371K
14.
Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population
Tarig Elraiyah, Calvin R. Jerde, Shikshya Shrestha, Rentian Wu, Qian Nie, Nasra H. Giama, Vivekananda Sarangi, Lewis R. Roberts, Steven M. Offer, Robert B. Diasio
Clin Pharmacol Ther. Author manuscript; available in PMC 2018 Mar 1.
Published in final edited form as: Clin Pharmacol Ther. 2017 Mar; 101(3): 382–390. Published online 2016 Nov 26. doi: 10.1002/cpt.531
PMCID:
PMC5309195
AbstractArticlePDF–935K
15.
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
Kelly E. Caudle, Henry M. Dunnenberger, Robert R. Freimuth, Josh F. Peterson, Jonathan D. Burlison, Michelle Whirl-Carrillo, Stuart A. Scott, Heidi L. Rehm, Marc S. Williams, Teri E. Klein, Mary V. Relling, James M. Hoffman
Genet Med. 2017 Feb; 19(2): 215–223. Published online 2016 Jul 21. doi: 10.1038/gim.2016.87
PMCID:
PMC5253119
AbstractArticlePDF–546K
16.
Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity
Wen Wee Ma, Muhammad Wasif Saif, Bassel F. El‐Rayes, Marwan G. Fakih, Thomas H. Cartwright, James A. Posey, Thomas R. King, Reid W. von Borstel, Michael K. Bamat
Cancer. 2017 Jan 1; 123(2): 345–356. Published online 2016 Sep 13. doi: 10.1002/cncr.30321
PMCID:
PMC5248610
AbstractArticlePDF–536K
17.
Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition
Guo Yu, Guo-Fu Li, John S. Markowitz
J Child Adolesc Psychopharmacol. 2016 May 1; 26(4): 314–326. doi: 10.1089/cap.2015.0137
PMCID:
PMC4876529
AbstractArticlePDF–489K
18.
Pharmacogenetic Allele Nomenclature: International Workgroup Recommendations for Test Result Reporting
Lisa V. Kalman, José A.G. Agúndez, Malin Lindqvist Appell, John Logan Black, Gillian C. Bell, Sotiria Boukouvala, Carsten Bruckner, Elspeth Bruford, Carsten Bruckner, Kelly Caudle, Sally Coulthard, Ann K. Daly, Andria L. Del Tredici, Johan T den Dunnen, Katarzyna Drozda, Robin Everts, David Flockhart, Robert Freimuth, Andrea Gaedigk, Houda Hachad, Toinette Hartshorne, Magnus Ingelman-Sundberg, Teri E. Klein, Volker M. Lauschke, Donna R. Maglott, Howard L. McLeod, Gwendolyn A. McMillin, Urs A. Meyer, Daniel J. Müller, Deborah A. Nickerson, William S. Oetting, Michael Pacanowski, Victoria M. Pratt, Mary V. Relling, Ali Roberts, Wendy S. Rubinstein, Katrin Sangkuhl, Matthias Schwab, Stuart A. Scott, Sarah C Sim, Ranjit K Thirumaran, Lorraine H. Toji, Rachel Tyndale, Ron HN van Schaik, Michelle Whirl-Carrillo, Kiang-Teck J Yeo, Ulrich M. Zanger
Clin Pharmacol Ther. Author manuscript; available in PMC 2017 Feb 1.
Published in final edited form as: Clin Pharmacol Ther. 2016 Feb; 99(2): 172–185. Published online 2015 Nov 20. doi: 10.1002/cpt.280
PMCID:
PMC4724253
AbstractArticlePDF–673K
19.
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients
Marzia Del Re, Angela Michelucci, Angelo Di Leo, Maurizio Cantore, Roberto Bordonaro, Paolo Simi, Romano Danesi
EPMA J. 2015; 6(1): 17. Published online 2015 Sep 2. doi: 10.1186/s13167-015-0039-x
PMCID:
PMC4556010
AbstractArticlePDF–399K
20.
DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)
Adam M. Lee, Qian Shi, Emily Pavey, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Jeffrey L. Berenberg, Richard M. Goldberg, Robert B. Diasio
J Natl Cancer Inst. 2014 Dec; 106(12): dju298. Published online 2014 Nov 5. doi: 10.1093/jnci/dju298
PMCID:
PMC4271081
AbstractArticlePDF–1.0M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center